Literature DB >> 20573836

V(alpha)14iNKT cells promote liver pathology during adenovirus infection by inducing CCL5 production: implications for gene therapy.

Maureen N Ajuebor1, Qingling Chen, Robert M Strieter, Patrick A Adegboyega, Tak Yee Aw.   

Abstract

Replication-defective recombinant adenoviruses are the most widely studied replication-defective vectors for the potential treatment of inherited human diseases. However, broad clinical application of replication-defective adenoviruses in gene therapy is being hindered by the induction of vigorous innate and adaptive immune responses against the vector that cause deleterious effects in the liver. V(alpha)14 invariant natural killer T cells (V(alpha)14iNKT cells) are thymus-derived innate T cells at the interface between the two arms of the immune response and provide full engagement of host defense. The pathophysiological role of intrahepatic V(alpha)14iNKT cells during replication-defective adenovirus infection is not known and is the main focus of our study. Our data showed that intrahepatic V(alpha)14iNKT cells were activated in response to adenovirus infection to induce significant levels of hepatic chemokine (C-C motif) ligand 5 (CCL5) and subsequent liver toxicity. Moreover, intrahepatic CCL5 production was selectively reduced by V(alpha)14iNKT cell deficiency. In vivo studies utilizing CCL5-deficient mice or V(alpha)14iNKT cell-deficient mice demonstrated that CCL5 deficiency or V(alpha)14iNKT cell deficiency was associated with reduced liver pathology. Similar results were seen after blocking the biological effects of the CCL5 receptors. In conclusion, we have identified an important proinflammatory role for activated intrahepatic V(alpha)14iNKT cells in positively influencing hepatic CCL5 production to promote acute liver inflammation and injury. Therefore, our findings highlight the blockade of CCL5 interaction with a cognate receptor(s) as an important potential strategy to alleviate liver pathology associated with replication-defective adenovirus infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573836      PMCID: PMC2919001          DOI: 10.1128/JVI.00605-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  The NKT cell system: bridging innate and acquired immunity.

Authors:  Masaru Taniguchi; Ken-Ichiro Seino; Toshinori Nakayama
Journal:  Nat Immunol       Date:  2003-12       Impact factor: 25.606

Review 2.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

3.  Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A.

Authors:  S Küsters; F Gantner; G Künstle; G Tiegs
Journal:  Gastroenterology       Date:  1996-08       Impact factor: 22.682

Review 4.  Cellular responses to interferon-gamma.

Authors:  U Boehm; T Klamp; M Groot; J C Howard
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

Review 5.  Adenoviruses as gene-delivery vehicles.

Authors:  J M Wilson
Journal:  N Engl J Med       Date:  1996-05-02       Impact factor: 91.245

6.  Toll-like receptor 3 ligand dampens liver inflammation by stimulating Valpha 14 invariant natural killer T cells to negatively regulate gammadeltaT cells.

Authors:  Tommy R Gardner; Qingling Chen; Yijun Jin; Maureen N Ajuebor
Journal:  Am J Pathol       Date:  2010-02-18       Impact factor: 4.307

7.  Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist.

Authors:  A E Proudfoot; C A Power; A J Hoogewerf; M O Montjovent; F Borlat; R E Offord; T N Wells
Journal:  J Biol Chem       Date:  1996-02-02       Impact factor: 5.157

8.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

Authors:  Y Yang; H C Ertl; J M Wilson
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

9.  Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4.

Authors:  Stacey R Vlahakis; Angelina Villasis-Keever; Timothy S Gomez; Gary D Bren; Carlos V Paya
Journal:  J Infect Dis       Date:  2003-11-18       Impact factor: 5.226

10.  Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2.

Authors:  Leonid S Metelitsa; Hong-Wei Wu; Hong Wang; Yujun Yang; Zamir Warsi; Shahab Asgharzadeh; Susan Groshen; S Brian Wilson; Robert C Seeger
Journal:  J Exp Med       Date:  2004-05-03       Impact factor: 14.307

View more
  5 in total

Review 1.  Targeting the diverse immunological functions expressed by hepatic NKT cells.

Authors:  Caroline C Duwaerts; Stephen H Gregory
Journal:  Expert Opin Ther Targets       Date:  2011-05-13       Impact factor: 6.902

2.  Early IL-17 production by intrahepatic T cells is important for adaptive immune responses in viral hepatitis.

Authors:  Lifei Hou; Zuliang Jie; Mayura Desai; Yuejin Liang; Lynn Soong; Tian Wang; Jiaren Sun
Journal:  J Immunol       Date:  2012-12-10       Impact factor: 5.422

3.  Vα14iNKT cell deficiency prevents acetaminophen-induced acute liver failure by enhancing hepatic glutathione and altering APAP metabolism.

Authors:  Isaac Downs; Tak Yee Aw; Jianfeng Liu; Patrick Adegboyega; Maureen N Ajuebor
Journal:  Biochem Biophys Res Commun       Date:  2012-10-15       Impact factor: 3.575

4.  Hepatocyte growth factor in dampening liver immune-mediated pathology in acute viral hepatitis without compromising antiviral activity.

Authors:  Renan Aguilar-Valenzuela; Eric D Carlsen; Yuejin Liang; Lynn Soong; Jiaren Sun
Journal:  J Gastroenterol Hepatol       Date:  2014-04       Impact factor: 4.029

5.  The ROS scavenger, NAC, regulates hepatic Vα14iNKT cells signaling during Fas mAb-dependent fulminant liver failure.

Authors:  Isaac Downs; Jianfeng Liu; Tak Yee Aw; Patrick A Adegboyega; Maureen N Ajuebor
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.